1. PO.4.75 The anti-BDCA2 antibody biib059 improves joint and skin manifestations in patients with SLE and both active arthritis and rash. (27th September 2022) Authors: Van Vollenhoven, RF; Furie, RA; Kalunian, K; Werth, VP; Carroll, H; Huang, X; Musselli, C; Barbey, C; Franchimont, N Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0222 BIIB059, a monoclonal antibody targeting BDCA2, shows evidence of biological activity and early clinical proof of concept in subjects with active cutaneous le. (15th June 2017) Authors: Furie, R; Werth, VP; Merola, JF; Reynolds, TL; Stevenson, L; Wang, W; Smirnakis, K; Barbey, C; Musselli, C; Werneburg, B; Rabah, D; Franchimont, N Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 857 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0235 BIIB059, a monoclonal antibody targeting BCDA2 shows safety, tolerability, pharmacokinetics, pharmacodynamics in healthy volunteer subjects. (15th June 2017) Authors: Martin, D; Stevenson, L; Prasad, P; Smirnakis, K; Kao, A; Rabah, D; Wang, W; Barbey, C; Musselli, C; Franchimont, N Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 862 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗